Cargando…
Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
While amyloid-targeting therapies continue to predominate in the Alzheimer’s disease (AD) drug development pipeline, there is increasing recognition that to effectively treat the disease it may be necessary to target other mechanisms and pathways as well. In December 2019, The EU/US CTAD Task Force...
Autores principales: | Gauthier, Serge, Aisen, P. S., Cummings, J., Detke, M. J., Longo, F. M., Raman, R., Sabbagh, M., Schneider, L., Tanzi, R., Tariot, P., Weiner, M., Touchon, J., Vellas, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223540/ https://www.ncbi.nlm.nih.gov/pubmed/32420298 http://dx.doi.org/10.14283/jpad.2020.18 |
Ejemplares similares
-
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022) -
Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force
por: Aisen, P. S., et al.
Publicado: (2021) -
Using Digital Tools to Advance Alzheimer’s Drug Trials During a Pandemic: The EU/US CTAD Task Force
por: Kaye, Jeffrey, et al.
Publicado: (2021) -
Epidemiology and Financial Burden of Adult Chronic Hypoparathyroidism
por: Bjornsdottir, Sigridur, et al.
Publicado: (2022) -
Task Force on Reintegration
Publicado: (1991)